Clinical Trial Update: Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial compares cabazitaxel at 20 mg/m² vs 25 mg/m² with prednisone in metastatic castration-resistant prostate cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-10-11